WO2024085756A1 - Matériaux à changement de phase dans des réseaux polymères - Google Patents
Matériaux à changement de phase dans des réseaux polymères Download PDFInfo
- Publication number
- WO2024085756A1 WO2024085756A1 PCT/NL2023/050547 NL2023050547W WO2024085756A1 WO 2024085756 A1 WO2024085756 A1 WO 2024085756A1 NL 2023050547 W NL2023050547 W NL 2023050547W WO 2024085756 A1 WO2024085756 A1 WO 2024085756A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gelsat
- phase
- composition
- formula
- solution
- Prior art date
Links
- 239000012782 phase change material Substances 0.000 title claims abstract description 99
- 229920000642 polymer Polymers 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 claims abstract description 180
- 239000000178 monomer Substances 0.000 claims abstract description 114
- 238000000034 method Methods 0.000 claims abstract description 72
- 235000017281 sodium acetate Nutrition 0.000 claims description 73
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 claims description 64
- 229940087562 sodium acetate trihydrate Drugs 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 239000003505 polymerization initiator Substances 0.000 claims description 34
- 239000004971 Cross linker Substances 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- -1 cerium(IV)-nitrilotriacetic acid Chemical compound 0.000 claims description 16
- 238000000015 thermotherapy Methods 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 238000002844 melting Methods 0.000 claims description 12
- 230000008018 melting Effects 0.000 claims description 12
- 125000006850 spacer group Chemical group 0.000 claims description 10
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical group [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- QHFQAJHNDKBRBO-UHFFFAOYSA-L calcium chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ca+2] QHFQAJHNDKBRBO-UHFFFAOYSA-L 0.000 claims description 4
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 claims description 4
- 229940044631 ferric chloride hexahydrate Drugs 0.000 claims description 4
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 claims description 4
- XNCMOUSLNOHBKY-UHFFFAOYSA-H iron(3+);trisulfate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O XNCMOUSLNOHBKY-UHFFFAOYSA-H 0.000 claims description 4
- IEMMJPTUSSWOND-UHFFFAOYSA-N lithium;nitrate;trihydrate Chemical compound [Li+].O.O.O.[O-][N+]([O-])=O IEMMJPTUSSWOND-UHFFFAOYSA-N 0.000 claims description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 4
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 claims description 4
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 claims description 4
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 claims description 4
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 claims description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- LXEKPEMOWBOYRF-UHFFFAOYSA-N [2-[(1-azaniumyl-1-imino-2-methylpropan-2-yl)diazenyl]-2-methylpropanimidoyl]azanium;dichloride Chemical compound Cl.Cl.NC(=N)C(C)(C)N=NC(C)(C)C(N)=N LXEKPEMOWBOYRF-UHFFFAOYSA-N 0.000 claims description 3
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 3
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 abstract description 13
- 125000002843 carboxylic acid group Chemical group 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 125000003368 amide group Chemical group 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 34
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 29
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 29
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 28
- 238000002425 crystallisation Methods 0.000 description 28
- 230000008025 crystallization Effects 0.000 description 28
- 238000005191 phase separation Methods 0.000 description 20
- 238000001816 cooling Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 238000007334 copolymerization reaction Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- 239000001632 sodium acetate Substances 0.000 description 10
- 238000004781 supercooling Methods 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 230000001351 cycling effect Effects 0.000 description 8
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- 230000001960 triggered effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000007101 Muscle Cramp Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 208000005392 Spasm Diseases 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005580 one pot reaction Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 206010023230 Joint stiffness Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 238000003892 spreading Methods 0.000 description 3
- 230000007480 spreading Effects 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000005102 attenuated total reflection Methods 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005489 elastic deformation Effects 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 125000004474 heteroalkylene group Chemical group 0.000 description 2
- 125000005549 heteroarylene group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000010309 melting process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010036 cardiovascular benefit Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IQIJRJNHZYUQSD-UHFFFAOYSA-N ethenyl(phenyl)diazene Chemical compound C=CN=NC1=CC=CC=C1 IQIJRJNHZYUQSD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940032296 ferric chloride Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- YHGPYBQVSJBGHH-UHFFFAOYSA-H iron(3+);trisulfate;pentahydrate Chemical compound O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O YHGPYBQVSJBGHH-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000006262 metallic foam Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000002064 nanoplatelet Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003211 polymerization photoinitiator Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000012719 thermal polymerization Methods 0.000 description 1
- 230000000930 thermomechanical effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K5/00—Heat-transfer, heat-exchange or heat-storage materials, e.g. refrigerants; Materials for the production of heat or cold by chemical reactions other than by combustion
- C09K5/02—Materials undergoing a change of physical state when used
- C09K5/06—Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice versa
- C09K5/063—Materials absorbing or liberating heat during crystallisation; Heat storage materials
Definitions
- compositions comprising a phase-change material and a polymer network, and methods of making or using same.
- phase change materials have drawn huge attention because of their ability to fulfil the inconsistency of traditional heat harvesting and to achieve heat management in a green, non-toxic and purely physical way.
- organic PCMs inorganic PCMs are more advantageous, since the latter are non-flammable, have a higher energy density, typically only demonstrate a slight volume change during phase transition, etc.
- Inorganic PCMs typically comprise salt hydrates.
- PCMs may phase-separate, severely limiting its long-term use.
- this problem is often observed when salt hydrates are used as PCMs.
- the liquid-solid phase separation can cause an inconsistent distribution of energy density inside the material, and as the cycling time increases, the phenomenon will only become worse.
- thickening agents Even when thickening agents are added, phase separation is only postponed to an unsatisfactory extent. Thus, the addition of thickening agents does not provide a long-term solution to phase-separation. Moreover, some thickening agents such as xanthan gum can also affect the heat transfer and lower the thermal conductivity of the PCM.
- PCMs polystyrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene, polystyrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-sty
- the present invention pertains to a composition
- the invention in another aspect, relates to a method for preparing a composition as defined in any one of the preceding claims, wherein said method comprises the steps of: a) contacting the phase-change material as defined herein with a polymer network as defined herein; or b) contacting the phase-change material as defined herein, with a solvent, a polymerization initiator, and the at least three monomers as defined herein; so as to obtain a second solution; and c) copolymerizing the at least three monomers in the second solution.
- the invention also relates to a composition obtainable by a method according to the invention.
- the invention also pertains to a composition according to the invention for use as a medicament.
- the invention also relates to a composition according to the invention for use in thermotherapy.
- the invention also pertains to a non-therapeutic use of a composition according to the invention as a heat supply; and/or for the thermal management of an electronic device; preferably the heat supply is a household heat supply; and preferably the electronic device is a flexible electronic device.
- Figure 1 depicts the synthesis of GELSAT-# (with # being 2, 4, 6, or 8), which is a composition according to the invention.
- Figure 2 depicts in panel (a) the DSC curves and heat of fusion of GELSAT-2, GELSAT-4, GELSAT-6, GELSAT-8, and SAT; in panels (b)-(d) GELSAT-4 in different rotation angles; and in panel (e) the flexibility of GELSAT-4.
- Figure 3 depicts in panel (a) supercooled SAT; in panel (b) supercooled GELSAT-4F (comparative example) before cycling; in panel (c) supercooled GELSAT-4F after 1 cycle; in panel (d) XRD results of GELSAT-4; and in panel (e) XRD results of GELSAT-4F.
- Figure 4 depicts in panel (a) FTIR of polyacrylic acid (PAA), polyacrylamide (PAM), and a copolymer of acrylic acid and acrylamide (PAA-co-PAM), SAT and GELSAT-4; in panel (b) the schematic structure of a comparative example, viz. GELSAT-4F with leakage; in panel (c) the schematic structure of GELSAT according to the invention; and in panel (d) a schematic representation of the molecular interactions of which the inventors believe are present within GELSAT according to the invention.
- Figure 5 depicts in panel (a) the melting process of GELSAT-4; and in panel (b) the UV-vis results of pure water and GELSAT-4.
- Figure 6 depicts in panel (a) the elastic deformation of supercooled GELSAT-6 while being squeezed and while lifting a metal cylinder of 50 g; in panel (b) the stretch of supercooled GELSAT-6; and in panel (c) a 50 g metal cylinder standing on the solidified GELSAT-6.
- Figure 8 depicts in panel (a) the crystallization process of GELSAT-4; and in panel (b) the crystallization process of GELSAT-6.
- Figure 9 depicts in panel (a) the DSC results of GELSAT-4 before and after cycles; and in panel (b) TGA analysis of pure SAT and GELSAT-4.
- Figure 10 depicts in panel (a) the heating-cooling curve of the samples at the 1 st cycle; and in panel (b) the heating-cooling curve of the samples at the 7 th cycle.
- Figure 11 depicts in panel (a) the crystallization curve of GELSAT-4 at the 1 st and 7 nd cycle, and in panel (b) the crystallization curve of GELSAT-6 at the 1 st and 7 th cycle.
- Figure 12 depicts the thermal conductivity results of pure SAT, GELSAT-4 and GELSAT-6.
- Figure 13 depicts the results from Example 7, wherein GELSAT-4 is made using varying wt/wt ratios of acrylamide (AAM) and acrylic acid (AA), from 10:90 to 80:20. The different compositions were subjected to one heating-cooling cycle.
- AAM acrylamide
- AA acrylic acid
- Figure 14 depicts the results from Example 7, viz. the triggering of crystallization in GELSAT-4 using electrodes.
- Panel (a) shows GELSAT-4 with electrodes inserted therein before applying a voltage
- panel (b) shows the setup directly after applying a voltage
- panel (c) shows that crystallization proceeds through the entire composition of GELSAT-4.
- compositions according to the invention are flexible, provide improved latent heat, demonstrate excellent cycling stability (e.g. reduced phase separation, stable heat generation, and/or reduced shrinkage upon cycling), can be transparent, and/or can be produced using green methods.
- cycling stability e.g. reduced phase separation, stable heat generation, and/or reduced shrinkage upon cycling
- the compositions of the invention can be prepared at low cost, and can be finetuned if necessary to meet specific requirements.
- the inventors believe that the advantageous properties of the composition arise from the combination of monomer residues in the polymer network, in particular the combination of monomer residues P and Q as described herein, which are the polymerized forms of monomers of Formula (1) and Formula (2), respectively. Still without wishing to be bound by theory, the inventors believe that the combination of amide groups in P and the carboxylic acid groups (and their conjugated bases) or esters in Q do not only improve the mechanical properties of the composition of the invention, but also the crystallization of the phase-change material.
- indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there is one and only one of the elements.
- the indefinite article “a” or “an” thus usually means “at least one”.
- the compounds may occur in different tautomeric forms.
- the compounds according to the invention are meant to include all tautomeric forms, unless stated otherwise.
- the structure of a compound is depicted as a specific tautomer, it is to be understood that the invention of the present application is not limited to that specific tautomer, unless stated otherwise.
- the compounds of the invention and/or groups thereof may be protonated or deprotonated. It will be understood that it is possible that a compound may bear multiple charges which may be of opposite sign. For example, in a compound containing an amine and a carboxylic acid, the amine may be protonated while simultaneously the carboxylic acid is deprotonated.
- Phase-change material refers to a substance which releases/absorbs sufficient energy at phase transition to provide useful heat or cooling.
- phase-change material can refer to the substance itself, or the entire material containing said substance.
- phase-change material refers to the substance itself, preferably to a salt hydrate, and not the material containing said substance. Typically, herein said material is referred to as “the composition”.
- a “cycle” refers to a phase-change material transitioning from one phase to another and back to the original phase.
- salts in particular salt hydrates, mentioned herein, insofar as appropriate also their ionic forms are intended to be covered. It will be understood that if a salt is dissolved, the ions making up the salt generally dissociate. Thus, in embodiments wherein the salts as described herein are dissolved, “salt” should be interpreted as referring to the ions originally making up said salt.
- alkyl In several chemical formulae and texts below reference is made to “alkyl”, “heteroalkyl”, “aryl”, “heteroaryl”, “alkylene”, “arylene”, “arenetriyl”, and the like.
- a butyl group substituted with a -OCH3 group is designated as a C4 alkyl, because the carbon atom in the substituent is not included in the carbon count.
- Unsubstituted alkyl groups have the general formula C n H2n+i and may be linear or branched.
- the alkyl groups are substituted by one or more substituents further specified in this document.
- the alkyl groups are not substituted. Examples of alkyl groups include methyl, ethyl, propyl, 2-propyl, t-butyl, 1 -hexyl, 1 -dodecyl, etc.
- An aryl group refers to an aromatic hydrocarbon ring system, and may include monocyclic and polycyclic structures. When the aryl group is a polycyclic structure, it is preferably a bicyclic structure. Optionally, the aryl group may be substituted by one or more substituents further specified in this document. Examples of aryl groups are phenyl and naphthyl.
- Heteroaryl groups comprise at least two carbon atoms (i.e. at least C2) and one or more heteroatoms N, O, P or S.
- heteroaryl groups comprise at least two carbon atoms (i.e. at least C2) and one or more oxygen atoms.
- a heteroaryl group may have a monocyclic or a bicyclic structure.
- the heteroaryl group may be substituted by one or more substituents further specified in this document.
- heteroaryl groups examples include pyridinyl, quinolinyl, pyrimidinyl, pyrazinyl, pyrazolyl, imidazolyl, thiazolyl, pyrrolyl, furanyl, triazolyl, benzofuranyl, indolyl, purinyl, benzoxazolyl, thienyl, phospholyl and oxazolyl.
- the prefix hetero- denotes that the group contains one or more heteroatoms selected from the group consisting of O, N, S, P, and Si.
- the groups with the prefix hetero- contain one or more oxygen atoms.
- the suffix -ene denotes divalent groups, i.e. that the group is linked to at least two other moieties.
- An example of an alkylene is propylene (-CH2-CH2-CH2-), which is linked to another moiety at both termini.
- the suffix -triyl denotes trivalent groups, i.e. that the group is linked to at least three other moieties.
- An example of an arenetriyl is depicted below: wherein the wiggly lines denote bonds to different groups of the main compound.
- any group disclosed herein is understood to be linear or branched.
- alkyl groups, alkenyl groups, alkanetriyl groups, heteroalkanetriyl groups, and the like are linear or branched, unless stated otherwise.
- Dalton The unified atomic mass unit or Dalton is herein abbreviated to Da.
- Dalton is a regular unit for molecular weight and that 1 Da is equivalent to 1 g/mol (grams per mole).
- the composition of the invention comprises a phase-change material and a polymer network.
- the phase-change material is dispersed within the polymer network, as shown in Figures 4(c)-(d).
- the phase-change material is a salt hydrate
- the salt hydrate may dissociate into a cation, an anion, and water molecules, after which one or more of these components may move through the polymer network, and/or interact with said polymer network either physically, chemically, or both.
- the composition of the invention comprises the phase-change material in an amount of from 81 wt% to 99 wt%, more preferably of from 83 wt% to 98 wt%, even more preferably of from 85 wt% to 97 wt%, more preferably still of from 87 wt% to 96 wt%, and most preferably of from 89 wt% to 95 wt%, as compared to the total weight of the composition.
- phase-change material is present in said composition in an amount of from 92 wt% to 96 wt%, more preferably of from 93 wt% to 95 wt%, and most preferably of from 93.5 wt% to 94.5 wt%, as compared to the total weight of the composition.
- the composition of the invention comprises the polymer network in an amount of from 1.0 wt% to 19.0 wt%, more preferably of from 1.5 wt% to 15.0 wt%, even more preferably of from 2.0 wt% to 10.0 wt%, yet more preferably of from 2.5 wt% to 9.0 wt%, more preferably still of from 3.0 wt% to 8.0 wt%, and most preferably of from 3.5 wt% to 7.5 wt%, as compared to the total weight of the composition.
- composition of the invention comprises the polymer network in an amount of from 3.4 wt% to 4.2 wt%, more preferably of from 3.5 wt% to 4.0 wt%, most preferably of from 3.6 wt% to 3.9 wt%, as compared to the total weight of the composition.
- the composition of the invention comprises the phase-change material in an amount of from 81 wt% to 99 wt%, more preferably of from 83 wt% to 98 wt%, even more preferably of from 85 wt% to 97 wt%, more preferably still of from 87 wt% to 96 wt%, and most preferably of from 88 wt% to 95 wt%, as compared to the dry weight of the composition.
- dry weight refers to the weight of the dry matter of the composition, viz. without the weight of any liquid, and that for the calculation of the amount of phase-change material as compared to the dry weight, the anhydrous form of said phase-change material is chosen if said phase-change material is a salt hydrate.
- the composition of the invention comprises the polymer network in an amount of from 2.0 wt% to 25.0 wt%, more preferably of from 2.5 wt% to 20.0 wt%, even more preferably of from 3.0 wt% to 17.5 wt%, yet more preferably of from 3.5 wt% to 15.0 wt%, more preferably still of from 4.0 wt% to 13.0 wt%, and most preferably of from 5 wt% to 12.0 wt%, as compared to the dry weight of the composition.
- composition of the invention may comprise a liquid, preferably water. It will be understood that in case the phase-change material is a salt hydrate, said water is additional to the water originating from the salt hydrate. As such, the composition of the invention is preferably a hydrogel.
- the liquid preferably water
- the liquid is present in the composition in an amount of from 0.5 wt% to 9.5 wt%, more preferably of from 0.8 wt% to 7.5 wt%, even more preferably of from 1.0 wt% to 5.0 wt%, yet more preferably of from 1.3 wt% to 4.5 wt%, more preferably still of from 1.5 wt% to 4.0 wt%, and most preferably of from 1.75 wt% to 3.75 wt%, as compared to the total weight of the composition.
- the composition of the invention consists essentially of the polymer network and the phase-change material, and optionally the liquid, all as defined herein.
- the total water content in the composition of the invention is at most 60 wt%, more preferably at most 55 wt%, even more preferably at most 50 wt%, yet more preferably at most 47 wt%, more preferably still at most 45 wt%, and most preferably at most 40 wt%, as compared to the total weight of the composition.
- the total water content includes any optionally added water, and the water contained in the phase-change material if the phase-change material is a salt hydrate.
- the total water content in the composition of the invention is in an amount of from 0.5 wt% to 60 wt%, more preferably of from 5 wt% to 55 wt%, even more preferably of from 10 wt% to 50 wt%, yet more preferably of from 20 wt% to 47 wt%, more preferably still of from 25 wt% to 45 wt%, and most preferably of from 35 wt% to 40 wt%, as compared to the total weight of the composition.
- composition of the invention does not require the presence of components other than the polymer network and phase-change material as described herein, said composition may contain one or more additives if desired.
- additives include colorants, fillers, thickening agents, and photon capturers (such as CuS). Nevertheless, to reduce the number of resources required and hence costs, it is preferred that the composition of the invention does not include such additives.
- the polymer network as used in the invention is a copolymer, preferably a random copolymer, comprising a structure according to Formula (A):
- CL indicates a crosslinker residue
- the wiggly lines indicate bonds to the rest of the copolymer.
- Suitable crosslinker residues for use in a copolymer of Formula (A) are known to the skilled person.
- Each Xi is independently selected from the group consisting of hydrogen and C1.3 alkyl.
- Xi is hydrogen or methyl, and most preferably Xi is hydrogen.
- Each X2 is independently selected from the group consisting of hydrogen and C1.3 alkyl.
- X2 is hydrogen or methyl, and most preferably X2 is hydrogen.
- Each X3 is independently selected from the group consisting of hydrogen and C1.3 alkyl.
- X3 is hydrogen or methyl, and most preferably X3 is hydrogen.
- the variables p, q, and r indicate the mole fractions of their respective monomer residues, viz. monomer residues P (i.e. the monomer residue comprising Xi), Q (i.e. the monomer residue comprising X2), and A (i.e. the monomer residue containing CL).
- additional monomer residues other than P, Q, and R may be present in the polymer network of the invention.
- the sum of the mole fractions p, q, and r is at least 0.7, more preferably at least 0.8, even more preferably at least 0.9, more preferably still at least 0.95, yet more preferably at least 0.97, and most preferably at least 0.99.
- 1 refers to the sum of all mole fractions of all monomer residues making up the polymer network.
- /? is larger than zero.
- q is larger than zero.
- r is larger than zero.
- the polymer network as used in the invention consists essentially of a structure according to Formula (A).
- the weight ratio of the monomer residues P and Q (i.e. the weight of P compared to the weight of Q) is at most 1 : 1, more preferably at most 1 : 1.5, more preferably at most 1 :2, more preferably still at most 1 :3, and most preferably at most 1 :4; with the proviso that both monomer residues P and Q are present in the polymer network.
- the weight ratio of the monomer residues P and Q (i.e. the weight of P compared to the weight of Q) is in a range of from 1 :25 to 2: 1, preferably from 1 : 10 to 1 : 1, more preferably of from 1 :9 to 1 :2, more preferably of from 1 :8 to 1 :2.5, more preferably of from 1 :6 to 1 :3, more preferably still of from 1 :4.5 to 1 :3.5, most preferably about 1 :4.
- the weight ratio of the monomer residue R as compared to the combined weight of all monomer residues is in a range of from 1 :80 to 1 : 10, preferably from 1 :60 to 1 : 15, more preferably of from 1 : 50 to 1 :20, more preferably still of from 1 : 40 to 1 :30, most preferably about 1 :33.
- copolymer of Formula (A) is a copolymer according to Formula (Al): Formula (Al)
- each X4 is independently selected from the group consisting of hydrogen and C1.3 alkyl.
- X4 is hydrogen or methyl, and most preferably X4 is hydrogen.
- each X5 indicates the remainder of the crosslinker residue.
- each X5 is independently selected from moi eties according to Formula (A2):
- n is 0 or 1, preferably each n is 1.
- S p is a spacer.
- the spacer can be of any length.
- spacers such as -NH-CH2-NH- in the commonly used N,RT - methylenebisacrylamide, or very long spacers (e.g. in crosslink 1 as disclosed in Postma et al., Angewandte Chemie International Edition 2017, volume 56, pages 1794-1798).
- spacer S p has a molecular weight of at most 2000 Da, more preferably at most 1500 Da, even more preferably at most 1000 Da, and most preferably at most 500 Da.
- the spacer S p is -NXs-Ci-ioalkyl-NXs-, wherein each X5 independently is hydrogen or C1.3 alkyl, preferably hydrogen. Most preferably, the spacer S p is -NH-CH2-NH-.
- the polymer network is obtainable by copolymerizing at least three monomers in a solution.
- the total concentration of said at least three monomers in said solution is of from 1 wt% to 19 wt% as compared to the total weight of the solution. It will be understood that this concentration refers to all monomers present in said solution taken together, and it is not intended that said solution comprises e.g. 19 wt% of a first monomer, 19 wt% of a second monomer, and 14 wt% of a third monomer.
- said total concentration of said at least three monomers in said solution is of from 1.5 wt% to 15.0 wt%, more preferably of from 2.0 wt% to 10.0 wt%, yet more preferably of from 2.5 wt% to 9.0 wt%, more preferably still of from 3.0 wt% to 8.0 wt%, and most preferably of from 3.5 wt% to 7.5 wt%, as compared to the total weight of the solution.
- said total concentration of said at least three monomers in said solution is of from 3.4 wt% to 4.2 wt%, more preferably of from 3.5 wt% to 4.0 wt%, most preferably of from 3.6 wt% to 3.9 wt%, as compared to the total weight of the solution.
- said at least three monomers comprise a monomer according to Formula (1), a monomer according to Formula (2), and a crosslinker. While other monomers may be present in said solution, it is preferred that at least 70 mol%, more preferably at least 80 mol%, even more preferably at least 90 mol%, more preferably still at least 95 mol%, yet more preferably at least 97 mol%, and most preferably at least 99 mol% of all monomers in said solution are the sum of the mole percentages of the monomer according to Formula (1), the monomer according to Formula (2), and the crosslinker. In preferred embodiments, said at least three monomers consist essentially of a monomer according to Formula (1), a monomer according to Formula (2), and a crosslinker.
- the weight ratio of the monomer of Formula (1), preferably acrylamide, over the monomer of Formula (2), preferably acrylic acid is at most 1 : 1, more preferably at most 1 : 1.5, more preferably at most 1 :2, more preferably still at most 1 :3, and most preferably at most 1 :4, with the proviso that said solution comprises both acrylamide and acrylic acid.
- the weight ratio of the monomer of Formula (1), preferably acrylamide, over the monomer of Formula (2), preferably acrylic acid is in a range of from 1 :25 to 2: 1, preferably from 1 : 10 to 1 : 1, more preferably of from 1 :9 to 1 :2, more preferably of from 1 :8 to 1 :2.5, more preferably of from 1 :6 to 1 :3, and most preferably of from 1 :5 to 1 :3.5.
- the weight ratio of the crosslinker, preferably N, N"- methylenebisacrylamide, as compared to the combined weight of all monomers in said solution is in a range of from 1 :80 to 1 : 10, preferably from 1 :60 to 1 : 15, more preferably of from 1 :50 to 1 :20, more preferably still of from 1 :40 to 1 :30, and most preferably about 1 :33.
- said solution further comprises a solvent.
- the solvent is selected from the group consisting of water, acetic acid, acetonitrile, dimethylformamide, dimethyl sulfoxide, methanol, benzene, butanol, n-butyl acetate, carbon tetrachloride, chloroform, cyclohexane, 1,2-di chloroethane, di chloromethane, diethyl ether, diisopropyl ether, ethyl acetate, heptane, hexane, isooctane, methyl ethyl ketone, methyl tert-butyl ether, pentane, toluene, trichloroethylene, and xylene.
- the solvent is selected from the group consisting of water, acetic acid, acetonitrile, dimethylformamide, dimethyl sulfoxide, and methanol. More preferably still, the solvent comprises water, and yet more preferably consists essentially of water. Most preferably, the solvent is water.
- the polymerization initiator is selected from the group consisting of persulfates, riboflavin, 2,2'-azobis(2-methylpropionamidine) dihydrochloride, camphorquinon, curcumin, eosin Y, Ru(bpy)3C12, a-ketoglutaric acid, and cerium(IV)- nitrilotriacetic acid. More preferably, the polymerization initiator is potassium persulfate or ammonium persulfate, and most preferably the polymerization initiator is potassium persulfate.
- the skilled person is aware of suitable temperatures at which the copolymerization can be conducted. Typically, ambient temperatures (e.g. of from 15°C to 30°C) are employed, but much higher temperatures can be used as well. Thus, preferably the temperature of the copolymerization is in a range of from 10°C to 90°C, and more preferably in a range of from 15°C to 85°C.
- Ri is selected from the group consisting of hydrogen and C1.3 alkyl. Preferably, Ri is hydrogen or methyl, and most preferably Ri is hydrogen.
- the monomer of Formula (1) is acrylamide or methacrylamide, most preferably acrylamide.
- R2 is selected from the group consisting of hydrogen and C1.3 alkyl.
- R2 is hydrogen or methyl, and most preferably R2 is hydrogen.
- R4 is selected from the group consisting of hydrogen and C1.3 alkyl.
- R4 is hydrogen or methyl, and most preferably R4 is hydrogen.
- the monomer of Formula (2) is acrylic acid or methacrylic acid, most preferably acrylic acid.
- the crosslinker monomer can be readily selected by the skilled person, and is generally suitable for copolymerization with a monomer of Formula (1) and a monomer of Formula (2).
- the crosslinker has a structure according to Formula (3):
- Each R3 independently is hydrogen or C1.3 alkyl, preferably each R3 is hydrogen or methyl, most preferably each R3 is hydrogen.
- the variable n and S p are as defined for Formula (A2).
- crosslinker according to Formula (3) is N,N"- m ethylenebisacrylamide.
- the composition of the invention comprises a phase-change material.
- the phase-change material is a salt.
- the phase-change material comprises a cation and an anion, and optionally water. More preferably, the phase-change material consists essentially of a cation and an anion, and optionally water.
- Preferred cations are sodium, potassium, lithium, calcium, magnesium, iron(III), and iron(II), more preferably sodium and potassium, and most preferably sodium.
- Preferred anions are acetate, chloride, nitrate, sulfate, thiosulfate, phosphate, hydrogen phosphate, and dihydrogen phosphate, most preferably acetate.
- the phase-change material is selected from the group consisting of sodium acetate trihydrate, calcium chloride hexahydrate, lithium nitrate trihydrate, sodium sulfate decahydrate, sodium hydrogen phosphate dodecahydrate, ferric chloride hexahydrate, sodium thiosulfate pentahydrate, magnesium sulfate heptahydrate, ferric sulfate heptahydrate, the anhydrous forms thereof, and combinations thereof.
- the anhydrous forms of said salts are sodium acetate, calcium chloride, lithium nitrate, sodium sulfate, sodium hydrogen phosphate, ferric chloride, sodium thiosulfate, magnesium sulfate, and ferric sulfate, respectively.
- anhydrous forms thereof refers to all salts preceding said phrase in the list presented in this paragraph, and that “combinations thereof’ refers to any combination of the anhydrous and/or hydrated forms of the salts listed in this paragraph.
- the phase-change material is a salt hydrate.
- Table 1 lists the preferred salt hydrates of the present invention and their respective phase-change temperatures (i.e. melting temperatures).
- Table 1 shows that the compositions of the invention can maintain a wide range of temperatures.
- these temperatures can be finetuned by combining two or more salt hydrates, and/or by tuning the properties of the polymer network.
- phase-change material is sodium acetate trihydrate (SAT).
- SAT is preferred because of its high latent heat (300 J/g), low cost, and phase change temperature of 58°C which renders it ideal for various applications.
- the invention also pertains to methods for preparing the composition according to the invention. These methods are economical and sustainable, since typically the materials used therein are used at an efficiency of 100% or close to 100% with no substantial waste or any substantial side product.
- the invention relates to a method for preparing a composition according to the invention, wherein said method comprises the steps of: a. contacting the phase-change material as defined herein with a polymer network as defined herein; or b. contacting the phase-change material as defined herein, with a solvent, a polymerization initiator, and the at least three monomers as defined herein; so as to obtain a second solution; and c. copolymerizing the at least three monomers in the second solution.
- said method comprises steps b and c rather than step a. While it is in principle possible to first prepare the polymer network and then contact said polymer network with a phase-change material as described herein, due to the typically high amounts of phasechange materials used in the compositions of the invention this procedure may not yield the best results. Instead, it is preferred to synthesize the polymer network as described herein in the presence of the phase-change material as defined herein, as done in steps b and c of the method of the invention.
- the solvent, polymerization initiator, the at least three monomers, and/or amounts thereof are as defined for the “polymer network obtainable by copolymerizing at least three monomers in a solution”.
- the solvent, polymerization initiator, the at least three monomers, and amounts thereof, in relation to said solution can also be applied to the second solution as mentioned in said steps b and c.
- step b preferably the phase-change material is present in said second solution in an amount of from 81 wt% to 99 wt%, more preferably of from 83 wt% to 98 wt%, even more preferably of from 85 wt% to 97 wt%, more preferably still of from 87 wt% to 96 wt%, and most preferably of from 89 wt% to 95 wt%, as compared to the total weight of the second solution.
- the phase-change material of the invention is preferably a salt hydrate.
- the method as described above comprises the steps of: i. melting the salt hydrate so as to obtain a melted salt hydrate; ii.
- the salt hydrate needs to be brought to a temperature above its melting temperature.
- the melting temperature is the same as the phase-change temperature, which are all known for known salt hydrates.
- the phase-change temperatures of the preferred salt hydrates of the invention are listed in Table 1. If the salt hydrate is the preferred sodium acetate trihydrate, it is preferred that in step i the salt hydrate is brought to a temperature of at least 58°C, preferably in a range of from 58°C to 100°C, more preferably 65°C to 95°C, more preferably still of from 70°C to 90°C, most preferably of from 75°C to 85°C, and typically of about 80°C.
- step ii preferably in said second solution the phase-change material is present in an amount of from 81 wt% to 99 wt%, more preferably of from 83 wt% to 98 wt%, even more preferably of from 85 wt% to 97 wt%, more preferably still of from 87 wt% to 96 wt%, and most preferably of from 89 wt% to 95 wt%, as compared to the total weight of the second solution.
- phase-change material is present in said second solution in an amount of from 92 wt% to 96 wt%, more preferably of from 93 wt% to 95 wt%, and most preferably of from 93.5 wt% to 94.5 wt%, as compared to the total weight of the second solution.
- the melted salt hydrate, solvent, polymerization initiator, and the at least three monomers can be contacted in any order. However, it is preferred to first contact the at least three monomers, the solvent, and the polymerization initiator, which can then be contacted with the melted salt hydrate. More preferably, the at least three monomers and the polymerization initiator are first dissolved in said solvent prior to contacting the resulting solution with the melted salt hydrate. This dissolving step can be performed at ambient temperatures, e.g. from 15°C to 30°C. By first dissolving the at least three monomers and the polymerization initiator prior to contacting them with the melted salt hydrate, a more well- controlled and evenly distributed polymerization process is typically observed.
- the polymerization initiator and at least three monomers are powders at room temperature, and if the polymerization initiator and the at least three monomers are still (partially) in solid form upon contact with the melted salt hydrate, the rates of polymerization may be different at different locations within the reaction mixture. While this may not necessarily present a major problem when preparing the composition of the invention, the best results are obtained when the polymerization initiator and the at least three monomers are dissolved in said solvent prior to contact the resulting solution with the melted salt hydrate.
- the second solution obtained in step ii is maintained at a temperature above the melting temperature of the salt hydrate. It will be understood that typically step iii of the invention is then initiated immediately after step ii is completed. Preferably, the second solution obtained in step ii is briefly mixed for at most 1 minute, preferably for at most 30 seconds, most preferably for at most 20 seconds. Mixing can be performed by any standard method known in the art, but stirring is preferred.
- the temperature in step iii of the method of the invention is at most 100°C, more preferably at most 90°C, and most preferably at most 85°C.
- a temperature in a range of from 60°C to 100°C, more preferably of from 70°C to 90°C, most preferably of from 75°C to 85°C is used, and typically of about 80°C.
- lower temperatures for copolymerization can be used, it is preferred to use a temperature of at least the melting temperature of the salt hydrate in step iii of the method of the invention. In that way, the salt hydrate maintains in its melted form during the copolymerization of the at least three monomers, which results in the best possible dispersion of the phase-change material in the resulting polymer network.
- the temperature in step iii is at least 58°C, more preferably in a range of from 58°C to 95°C, most preferably in a range of from 75°C to 85°C.
- the copolymerization in step iii is typically quite fast, and the polymer network is generally formed within minutes. It is preferred that the copolymerization is conducted for at least 5 minutes, more preferably at least 10 minutes, even more preferably at least 15 minutes, more preferably still at least 20 minutes, and most preferably at least 25 minutes. There is not necessarily an upper limit for the duration of the copolymerization step, since the reaction is typically complete or sufficiently complete within the time periods mentioned in the preceding sentence. For practical reasons, the copolymerization is preferably conducted for at most 1 day, more preferably at most 12 hours, at most 6 hours, at most 3 hours, at most 1.5 hours, and most preferably at most 45 minutes.
- the solvent, polymerization initiator, the at least three monomers, and/or amounts thereof are as defined for the “polymer network obtainable by copolymerizing at least three monomers in a solution”.
- the solvent, polymerization initiator, the at least three monomers, and amounts thereof, in relation to said solution can also be applied to the second solution as mentioned in said steps ii and iii.
- the invention also pertains to a composition obtainable by a method according to the invention, which is preferably characterized as disclosed herein in relation to compositions of the invention, in particular regarding the polymer network and phase-change material, and concentrations thereof.
- thermotherapy heat is applied to a subject in order to prevent or treat one or more symptoms of a disease.
- thermotherapy is typically used for pain relief, for the treatment of rheumatoid arthritis, increasing the extensibility of collagen tissues; decreasing joint stiffness; relieving muscle spasms; reducing inflammation, edema, and aids in the post-acute phase of healing; and increasing blood flow.
- the increased blood flow to the affected area provides proteins, nutrients, and oxygen for better healing.
- heat therapy can also aid in the treatment of neurodegenerative diseases like Alzheimer's; as well as for cardiovascular benefits.
- the compositions of the invention can also be used in therapeutic applications addressing one or more of these diseases and conditions, and/or achieve one or more of these therapeutic effects.
- the invention covers a composition according to the invention for use as a medicament. More particularly, the composition of the invention is for use in thermotherapy.
- the invention covers a phase-change material as defined herein dispersed in a polymer network as disclosed herein for use as a medicament, more preferably for use in thermotherapy.
- the therapeutic applications of the phasechange material are as defined herein for the composition of the invention.
- composition of the invention, or the phase-change material as defined herein dispersed in a polymer network as disclosed herein are also for use in treating or preventing pain, rheumatoid arthritisjoint stiffness, muscle spasms, inflammation, edema, cancer, neurodegenerative diseases, and cardiovascular diseases.
- a preferred neurodegenerative disease that can be treated with the invention is Alzheimer’s disease.
- the composition of the invention can be applied to the exterior or interior of a subject.
- the composition of the invention is applied to or close to the exterior of a subject.
- said composition is applied in such a way that sufficient heat can reach the body (e.g. skin, hair, nails, and the like) of the subject.
- the composition is preferably applied directly onto the body of the subject, it is also possible to leave some material such as clothes, plastic, towels, and the like between the subject’s body and the composition of the invention.
- the composition of the invention is applied to the interior of a subject, it is preferably applied directly or close to the part of the body that is to be treated, e.g. the brain, heart, tumour, liver, kidney, pancreas, lung, stomach, intestine, bladder, and the like.
- the subject is a mammal, more preferably a primate, and most preferably a human being.
- the disclosure also pertains to a method of treating or preventing a disease or condition in a subject, wherein said method comprises the step of applying the composition of the invention to a subject.
- the method of treatment pertains to thermotherapy.
- the disclosure also pertains to the use of a composition of the invention for the manufacture of a medicament.
- the medicament is for thermotherapy.
- the disclosure also pertains to the use of a composition of the invention for the manufacture of a medicament for the treatment or prevention of pain, rheumatoid arthritis oint stiffness, muscle spasms, inflammation, edema, cancer, neurodegenerative diseases, and cardiovascular diseases.
- compositions of the invention can also be advantageously applied in non- therapeutic applications.
- the invention also covers the use of a composition according to the invention as a heat supply.
- the composition according to the invention is used a household heat supply.
- the invention covers the use of a composition of the invention for the thermal management of an electronic device.
- the electronic devices are flexible.
- This use of the composition of the invention is particularly advantageous as compared to other materials, since the composition of the invention is typically flexible itself as well while it manages the temperature of the electronic device.
- long-term typically refers to at least one day, more preferably at least three days, more preferably at least a week, even more preferably at least two weeks, more preferably still at least three weeks, more preferably at least a month, more preferably at least six months, and most preferably at least a year.
- Embodiment 1 A composition comprising a phase-change material and a polymer network
- Embodiment 2 The composition according to Embodiment 1, wherein the phase-change material is dispersed within the polymer network.
- Embodiment 3 The composition according to any one of the preceding Embodiments, wherein the composition is a hydrogel.
- Embodiment 4 The composition according to any one of the preceding Embodiments, wherein the phase-change material is a salt.
- Embodiment 5 The composition according to any one of the preceding Embodiments, wherein the phase-change material is a salt hydrate.
- Embodiment 6 The composition according to any one of the preceding Embodiments, wherein the phase-change material is selected from the group consisting of sodium acetate trihydrate, calcium chloride hexahydrate, lithium nitrate trihydrate, sodium sulfate decahydrate, sodium hydrogen phosphate dodecahydrate, ferric chloride hexahydrate, sodium thiosulfate pentahydrate, magnesium sulfate heptahydrate, ferric sulfate heptahydrate, the anhydrous forms thereof, and combinations thereof.
- the phase-change material is selected from the group consisting of sodium acetate trihydrate, calcium chloride hexahydrate, lithium nitrate trihydrate, sodium sulfate decahydrate, sodium hydrogen phosphate dodecahydrate, ferric chloride hexahydrate, sodium thiosulfate pentahydrate, magnesium sulfate heptahydrate, ferric sulfate heptahydrate, the anhydrous forms thereof, and combinations
- Embodiment 7 The composition according to any one of the preceding Embodiments, wherein the phase-change material is selected from the group consisting of sodium acetate trihydrate, calcium chloride hexahydrate, lithium nitrate trihydrate, sodium sulfate decahydrate, sodium hydrogen phosphate dodecahydrate, ferric chloride hexahydrate, sodium thiosulfate pentahydrate, magnesium sulfate heptahydrate, ferric sulfate heptahydrate, and combinations thereof.
- the phase-change material is selected from the group consisting of sodium acetate trihydrate, calcium chloride hexahydrate, lithium nitrate trihydrate, sodium sulfate decahydrate, sodium hydrogen phosphate dodecahydrate, ferric chloride hexahydrate, sodium thiosulfate pentahydrate, magnesium sulfate heptahydrate, ferric sulfate heptahydrate, and combinations thereof.
- Embodiment 8 The composition according to any one of the preceding Embodiments, wherein the phase-change material is sodium acetate trihydrate.
- Embodiment 9 The composition according to any one of Embodiments 4-8, wherein the salt is in dissociated form, viz. dissociated into ions.
- Embodiment 10 The composition according to any one of the preceding Embodiments, wherein the phase change material comprises sodium ions and acetate ions.
- Embodiment 11 The composition according to any one of the preceding Embodiments, wherein said composition comprises the phase-change material in an amount of from 81 wt% to 99 wt%, more preferably of from 83 wt% to 98 wt%, even more preferably of from 85 wt% to 97 wt%, more preferably still of from 87 wt% to 96 wt%, and most preferably of from 89 wt% to 95 wt%, as compared to the total weight of the composition.
- Embodiment 12 The composition according to any one of the preceding Embodiments, wherein said composition comprises the phase-change material in an amount of from 92 wt% to 96 wt%, more preferably of from 93 wt% to 95 wt%, and most preferably of from 93.5 wt% to 94.5 wt%, as compared to the total weight of the composition.
- Embodiment 13 The composition according to any one of the preceding Embodiments, wherein said composition comprises the phase-change material in an amount of the phasechange material in an amount of from 81 wt% to 99 wt%, more preferably of from 83 wt% to 98 wt%, even more preferably of from 85 wt% to 97 wt%, more preferably still of from 87 wt% to 96 wt%, and most preferably of from 88 wt% to 95 wt%, as compared to the dry weight of the composition.
- Embodiment 14 The composition according to any one of the preceding Embodiments, wherein said composition comprises the phase-change material in an amount of the phasechange material in an amount of from 94.0 wt% to 98.0 wt%; more preferably of from 94.5 wt% to 97.5 wt%, more preferably of from 95.0 wt% to 97.0 wt%, and most preferably of from 95.5 wt% to 96.5 wt%, as compared to the dry weight of the composition.
- Embodiment 15 The composition according to any one of the preceding Embodiments, wherein said composition comprises the polymer network in an amount of from 1.0 wt% to 19.0 wt%, more preferably of from 1.5 wt% to 15.0 wt%, even more preferably of from 2.0 wt% to 10.0 wt%, yet more preferably of from 2.5 wt% to 9.0 wt%, more preferably still of from 3.0 wt% to 8.0 wt%, and most preferably of from 3.5 wt% to 7.5 wt%, as compared to the total weight of the composition.
- Embodiment 16 The composition according to any one of the preceding Embodiments, wherein said composition comprises the polymer network in an amount of from 3.4 wt% to 4.2 wt%, more preferably of from 3.5 wt% to 4.0 wt%, most preferably of from 3.6 wt% to 3.9 wt%, as compared to the total weight of the composition.
- Embodiment 17 The composition according to any one of the preceding Embodiments, wherein said composition comprises the polymer network in an amount of from 2.0 wt% to 25.0 wt%, more preferably of from 2.5 wt% to 20.0 wt%, even more preferably of from 3.0 wt% to 17.5 wt%, yet more preferably of from 3.5 wt% to 15.0 wt%, more preferably still of from 4.0 wt% to 13.0 wt%, and most preferably of from 5 wt% to 12.0 wt%, as compared to the dry weight of the composition.
- Embodiment 18 The composition according to any one of the preceding Embodiments, wherein the polymer network is a copolymer, preferably a random copolymer, comprising a structure according to Formula (A) as defined herein, preferably a structure according to Formula (Al) as defined herein.
- Embodiment 19 The composition according to any one of the preceding Embodiments, wherein the polymer network is a copolymer of acrylamide, acrylic acid, and TV, TV 7 - methylenebisacrylamide.
- Embodiment 20 The composition according to any one of the preceding Embodiments, wherein said composition further comprises a liquid, preferably water.
- Embodiment 21 The composition according to Embodiment 20, wherein said composition comprises the liquid, preferably water, in an amount of from 0.5 wt% to 9.5 wt%, more preferably of from 0.8 wt% to 7.5 wt%, even more preferably of from 1.0 wt% to 5.0 wt%, yet more preferably of from 1.3 wt% to 4.5 wt%, more preferably still of from 1.5 wt% to 4.0 wt%, and most preferably of from 1.75 wt% to 3.75 wt%, as compared to the total weight of the composition.
- Embodiment 22 Embodiment 22.
- composition according to Embodiment 20 wherein said composition comprises the liquid, preferably water, in an amount of from 1.5 wt% to 2.3 wt%, more preferably of from 1.6 wt% to 2.2 wt%, more preferably of from 1.7 wt% to 2.1 wt%, and most preferably of from 1.8 wt% to 2.0 wt%, as compared to the total weight of the composition.
- Embodiment 23 The composition according to any one of the preceding Embodiments, wherein the total water content in said composition is at most 60 wt%, more preferably at most 55 wt%, even more preferably at most 50 wt%, yet more preferably at most 47 wt%, more preferably still at most 45 wt%, and most preferably at most 40 wt%, as compared to the total weight of the composition; wherein the total water content includes any optionally added water, and the water contained in the phase-change material if the phase-change material is a salt hydrate.
- Embodiment 24 The composition according to any one of the preceding Embodiments, wherein the total water content in said composition is in an amount of from 0.5 wt% to 60 wt%, more preferably of from 5 wt% to 55 wt%, even more preferably of from 10 wt% to 50 wt%, yet more preferably of from 20 wt% to 47 wt%, more preferably still of from 25 wt% to 45 wt%, and most preferably of from 35 wt% to 40 wt%, as compared to the total weight of the composition; wherein the total water content includes any optionally added water, and the water contained in the phase-change material if the phase-change material is a salt hydrate.
- Formula (2) is H2C
- Embodiment 27 A method for preparing a composition as defined in any one of the preceding Embodiments, wherein said method comprises the steps of: a. contacting a phase-change material with a polymer network; or b. contacting a phase-change material, with a solvent, a polymerization initiator, and the at least three monomers as defined in Embodiment 21; so as to obtain a second solution; and c. copolymerizing the at least three monomers in the second solution.
- Embodiment 28 A method according to Embodiment 27, wherein said method comprises step a, wherein preferably step a comprises contacting a phase-change material with a polymer network and a solvent.
- Embodiment 29 A method according to any one of Embodiments 27-28, wherein said polymer network is as defined in any one of Embodiments 19, 20, and 26.
- Embodiment 30 A method according to Embodiment 27, wherein said method comprises steps b and c.
- Embodiment 31 A method according to any one of Embodiments 27-30, wherein said phasechange material is as defined in any one of Embodiments 4-10.
- Embodiment 32 A method according to any one of Embodiments 27, 28, and 31, wherein the phase-change material is a salt hydrate, preferably as defined in any one of Embodiment 6-10, and wherein the method comprises the steps of: i. melting the salt hydrate so as to obtain a melted salt hydrate; ii. contacting the melted salt hydrate with a solvent, a polymerization initiator, and the at least three monomers as defined in Embodiment 26, so as to obtain a second solution; and iii. copolymerizing the at least three monomers in the second solution at a temperature of at least the melting temperature of said salt hydrate.
- Embodiment 33 The method according to Embodiment 32, wherein the salt hydrate is sodium acetate trihydrate, and wherein the temperature in step iii is at least 58°C; wherein preferably the temperature in step iii is in a range of from 58°C to 95°C; and most preferably the temperature in step iii in a range of from 75°C to 85°C.
- Embodiment 34 The method according to any one of Embodiments 27 to 33, wherein the solvent comprises water; and preferably consists essentially of water.
- Embodiment 35 The composition according to Embodiment 26, or the method according to any one of Embodiments 27, and 30 to 34, wherein the polymerization initiator is selected from the group consisting of persulfates, riboflavin, 2,2 '-azobi s(2-methylpropionami dine) dihydrochloride, camphorquinon, curcumin, eosin Y, Ru(bpy)3Ch, a-ketoglutaric acid, and cerium(IV)-nitrilotriacetic acid; wherein preferably the polymerization initiator is potassium persulfate or ammonium persulfate; more preferably the polymerization initiator is potassium persulfate.
- the polymerization initiator is selected from the group consisting of persulfates, riboflavin, 2,2 '-azobi s(2-methylpropionami dine) dihydrochloride, camphorquinon, curcumin, eosin Y, Ru(
- Embodiment 36 The composition or method according to any one of Embodiments 26, 27, and 30-35, wherein the concentration of the at least three monomers in said solution or in said second solution is of from 1.5 wt% to 15.0 wt%; more preferably of from 2.0 wt% to 10.0 wt%, yet more preferably of from 2.5 wt% to 9.0 wt%; more preferably still of from 3.0 wt% to 8.0 wt%; and most preferably of from 3.5 wt% to 7.5 wt%, as compared to the total weight of said solution.
- Embodiment 37 The composition or method according to any one of Embodiments 26, 27, and 30-35, wherein the concentration of the at least three monomers in said solution or in said second solution is of from 3.4 wt% to 4.2 wt%, more preferably of from 3.5 wt% to 4.0 wt%, most preferably of from 3.6 wt% to 3.9 wt%, as compared to the total weight of the solution.
- Embodiment 38 The composition or method according to any one of Embodiments 26, 27, and 30-37, wherein in said solution or said second solution the weight ratio of the monomer 1 of Formula (1), preferably acrylamide, over the monomer of Formula (2), preferably acrylic acid, is at most 1 : 1, more preferably at most 1 : 1.5, more preferably at most 1 :2, more preferably still at most 1 :3, and most preferably at most 1 :4, with the proviso that said solution comprises both a monomer of Formula (1) and a monomer of Formula (2).
- the weight ratio of the monomer 1 of Formula (1), preferably acrylamide, over the monomer of Formula (2), preferably acrylic acid is at most 1 : 1, more preferably at most 1 : 1.5, more preferably at most 1 :2, more preferably still at most 1 :3, and most preferably at most 1 :4, with the proviso that said solution comprises both a monomer of Formula (1) and a monomer of Formula (2).
- Embodiment 39 The composition or method according to any one of Embodiments 26, 27, and 30-37, wherein in said solution or said second solution the weight ratio of the monomer of Formula (1) over the monomer of Formula (2) is in a range of from 1 :25 to 2: 1; preferably from 1 : 10 to 1 : 1; more preferably of from 1 :9 to 1 :2; more preferably of from 1 :8 to 1 :2.5; more preferably of from 1 :6 to 1 :3; and most preferably of from 1 :5 to 1 :3.5.
- Embodiment 40 The composition or method according to any one of Embodiments 26, 27, and 30-37, wherein the crosslinker has a structure according to Formula (3): (Formula (3)) wherein each R 3 independently is hydrogen or Ci- 3 alkyl; n is 0 or 1; and S p is a spacer; preferably each R 3 is hydrogen; preferably each n is 1; preferably S p is -NH-CFF-NH-; and preferably the crosslinker according to Formula (3) is A,7V’-methylenebisacrylamide.
- Formula (3) Formula (3) wherein each R 3 independently is hydrogen or Ci- 3 alkyl; n is 0 or 1; and S p is a spacer; preferably each R 3 is hydrogen; preferably each n is 1; preferably S p is -NH-CFF-NH-; and preferably the crosslinker according to Formula (3) is A,7V’-methylenebisacrylamide.
- Embodiment 41 The method according to any one of Embodiments 27, and 30-40, wherein in said second solution the phase-change material is present in an amount of from 81 wt% to 99 wt%, more preferably of from 83 wt% to 98 wt%, even more preferably of from 85 wt% to 97 wt%, more preferably still of from 87 wt% to 96 wt%, and most preferably of from 89 wt% to 95 wt%, as compared to the total weight of the second solution.
- Embodiment 42 The method according to any one of Embodiments 27, and 30-41, wherein in said second solution the phase-change material is present in an amount of from 92 wt% to 96 wt%, more preferably of from 93 wt% to 95 wt%, and most preferably of from 93.5 wt% to 94.5 wt%, as compared to the total weight of the second solution.
- Embodiment 43 A composition obtainable by a method according to any one of Embodiments 27 to 42.
- Embodiment 44 The composition according to Embodiment 43, wherein said composition is as defined in any one of Embodiments 1 to 26.
- Embodiment 45 The composition according to any one of Embodiments 1-26, 35-40, 43 and 44 for use as a medicament.
- Embodiment 46 The composition according to any one of 1-26, 35-40, 43 and 44 for use in thermotherapy.
- Embodiment 47 The composition according to any one of 1-26, 35-40, 43 and 44 for use in the treatment or prevention of pain, rheumatoid arthritis, joint stiffness, muscle spasms, inflammation, edema, cancer, neurodegenerative diseases, and cardiovascular diseases.
- Embodiment 48 A method of treating or preventing a disease or condition in a subject, wherein said method comprises the step of applying the composition according to any one of 1-26, 35-40, 43 and 44 to a subject.
- Embodiment 49 The method according to Embodiment 48, wherein the method of treatment pertains to thermotherapy.
- Embodiment 50 Use of a composition of any one of 1-26, 35-40, 43 and 44 for the manufacture of a medicament.
- Embodiment 51 The use of Embodiment 50, wherein the medicament is for thermotherapy.
- Embodiment 52 The use of Embodiment 50, wherein the medicament is for the manufacture of a medicament for the treatment or prevention of pain, rheumatoid arthritis joint stiffness, muscle spasms, inflammation, edema, cancer, neurodegenerative diseases, and cardiovascular diseases.
- Embodiment 53 Non-therapeutic use of a composition according to any one of 1-26, 35-40, 43 and 44 as a heat supply; and/or for the thermal management of an electronic device; preferably the heat supply is a household heat supply; and preferably the electronic device is a flexible electronic device.
- Embodiment 54 Non-therapeutic use of a composition according to any one of 1-26, 35-40, 43 and 44 for long-term storage of thermal energy, wherein preferably “long-term” refers to at least one day, more preferably at least three days, more preferably at least a week, even more preferably at least two weeks, more preferably still at least three weeks, more preferably at least a month, more preferably at least six months, and most preferably at least a year.
- long-term refers to at least one day, more preferably at least three days, more preferably at least a week, even more preferably at least two weeks, more preferably still at least three weeks, more preferably at least a month, more preferably at least six months, and most preferably at least a year.
- the one-pot synthesis of the composition of the invention consists of 4 steps. Firstly, pure sodium acetate trihydrate (SAT) was melted in an 80°C oil bath for 1 hour. Secondly, the desired monomers (typically acrylic acid and acrylamide and a crosslinker, preferably N,N'- methylenebisacrylamide (MBA)) were contacted with a polymerization initiator, preferably potassium persulfate (KPS), and a solvent, preferably water, to obtain a mixture.
- SAT sodium acetate trihydrate
- MSA N,N'- methylenebisacrylamide
- the mixture is stirred until the liquid is homogenous and clear.
- the SAT was totally melted, it was taken out of the oil bath, and contacted with said mixture from the last step to obtain a sample.
- the sample was stirred for 20 seconds at room temperature at 400 rpm to obtain a second mixture.
- the second mixture was poured into a sample bottle and put in an oven for 30 minutes at 80°C.
- phase-change materials in particular salt hydrates, can be employed instead of or in addition to SAT.
- GELSAT-# wherein # is a value (2, 4, 6, or 8) that represents the weight percentage of the polymer network relative to sodium acetate trihydrate (SAT).
- # is a value (2, 4, 6, or 8) that represents the weight percentage of the polymer network relative to sodium acetate trihydrate (SAT).
- the monomers were acrylic acid and acrylamide, wherein the amount of acrylamide used was 25 wt% as compared to the amount of acrylic acid used;
- the crosslinker was N,N'-methylenebisacrylamide, used in an amount of 3 wt% compared to the sum of the weight of the monomers (viz. the combined weight of acrylamide, acrylic acid and N,N' -methylenebisacrylamide); and (c) the weight percentage of added water used in the preparation of the mixture is half as much as the sum of the weight of the monomers (viz. the combined weight of acrylamide, acrylic acid and N,N' -methylenebisacrylamide).
- about 3 wt% thereof are residues of the crosslinker
- about 77.6 wt% are residues of acrylic acid
- about 19.4 wt% are residues of acrylamide.
- the water content of the GELSATs described herein can be kept constant, but it may also be lowered by e.g. evaporation during storage. Unless stated otherwise, the water content of the GELSATs described herein is kept constant.
- GELSAT-4F was prepared using the protocol of Example 1.
- GELSAT-4F is like GELSAT-4 in terms of SAT content, polymer content, crosslinker content, and the choice of crosslinker.
- acrylic acid is the only monomer used.
- GELSAT-4F does not contain residues of acrylamide, and thus the polymer network of GELSAT-4F consists of about 3 wt% of residues of the crosslinker, and about 97 wt% of residues of acrylic acid.
- Differential scanning calorimeter was used to characterize the phase change properties of the composition of the invention from 20°C to 80°C at a rate of 5°C min' 1 under a nitrogen atmosphere.
- a thermogravimetric analyzer was applied to test the thermal stability from room temperature up to 110°C at a rate of 10°C min' 1 under a nitrogen atmosphere.
- the thermal distribution during the phase change of composition of the invention was observed by an Infrared camera (HIKMICRO M10). Scanning electron microscope (SEM) images were taken to observe the morphology.
- the composition of the invention was examined by Fourier transform infrared spectroscopy (FTIR) with attenuated total reflectance (ATR).
- FTIR Fourier transform infrared spectroscopy
- ATR attenuated total reflectance
- the crystal structure was observed and analyzed by a polarizing microscope (POM) and the X-ray diffraction (XRD) method.
- Ultraviolet-visible (UV-vis) spectra was applied to show the transparency of the composition of the invention.
- the sample was put into a cuvette (12.5*12.5*45 mm) and triggered from the top under its supercooled state. The time and distance of a crystal growth from one point to another were recorded and the speed was calculated by dividing the distance by time. Three sets of data were recorded to ensure the accuracy.
- a Thermal Analyzer KD2-Pro, Decagon was used to measure the thermal conductivity of the composition of the invention.
- Figure 2(a) shows the DSC results of the GELSAT-2, GELSAT-4, GELSAT-6, GELSAT-8, and SAT.
- the exothermic peak is not included since all samples showed no exothermal behavior during cooling, indicating a large supercooling degree of at least over 30°C.
- the heat of fusion decreases as the weight percentage of polymers increases, while the onset temperature of phase change could vary from 50.4°C to 54°C.
- GELSAT-2 is still in a liquid state which has phase separation, so it is not an ideal sample for further studying even though it has a high latent heat of 271.4 J/g. The rest of the samples with higher portions of polymers all showed no phase separation.
- GELSAT-4 is a perfect representative which achieved no phase separation with the lowest ratio of polymers and high heat of fusion (264 J/g), which can be seen in Figure 2(a)-(d). Being a polymer-modified material, GELSAT-4 showed both good form stability and flexibility (Figure 2 (e)).
- FIG 3(b) shows the results for control product GELSAT-4F, of which the properties are evidently worse as compared to those of GELSAT-4.
- the phase separation of GELSAT-4F not only comes from the salt and the liquid, but also from the shrinkage of the polymer itself (see Figure 3(c)).
- transparency is the most evident difference that can be noticed when comparing GELSAT-4 to GELSAT-4F, with GELSAT-4 being transparent and GELSAT-4F being entirely opaque.
- SA anhydrous sodium acetate
- the PAM is not pH sensitive as it does not contain an ionizable group, it has a consistent structure and will not be affected by ion-shielding. This makes PAM a perfect binder for the copolymer chain to become more stretched, resulting in a better crosslinked network ( Figure 4 (c)). This improved crosslinking network not only eliminated phase separation completely, but also achieved a flexible structure. Other than this, both XRD results and the transparent appearance showed that there is no anhydrous SA appearing in the GELSAT-4, which further supported the inventor’s belief that the interaction between the polymers and the SAT is not only physical, but also chemical.
- GELSAT -4 was displayed in a sample bottle of 30 mm in diameter and the depth of the sample is 5 mm.
- a paper with the logo of the University of Twente was put beneath the sample bottle and the photos were taken from the top.
- FIG 5(a) The switch of two different states of GELSAT-4 when being heated up could be observed as the transparency changes (from solid to soft gel).
- GELSAT-4 has excellent transparency as the logo beneath it can be seen clearly.
- a UV-vis test was performed to verify the transparency of the supercooled GELSAT - 4, as shown in Figure 5(b).
- the transmittance range of GELSAT-4 is from 77.6% to 81.1%.
- the energy state of the material can be easily recognized from its appearance. This is surprising, since this was not achieved by previous SAT -based materials, because the modifications applied to eliminate the phase separation always made the whole material opaque. This unique property brings the GELSAT lots of possibilities in real applications since the energy status of the material can be easily recognized at the first sight.
- GELSAT-6 was polymerized in a cylinder mold (30 mm in diameter, 70 mm in height) as a sample.
- the reason to choose GELSAT-6 is that, GELSAT-6 contains more polymers which help to form a stronger network, resulting in better shape stability compared to GELSAT-4.
- Figure 6(a) shows the elastic deformation of supercooled GELSAT-6 when attaching to a metal cylinder of 50 g at its bottom. GELSAT-6 could not only be squeezed but also be stretched by the weight of the metal. Additionally, GELSAT-6 could be easily stretched to 2 times its original length ( Figure 6(b)).
- the stiffness of the GELSAT could enable it to stand the weight of the same metal cylinder on top of it, as shown in Fig. 6 (c).
- the phase change of GELSAT also brings interesting reversible switches between two different mechanical states, from flexible to formstable.
- the presence of polymers inside the GELSAT-4 also resulted in a smaller crystal size and slower growth rate (as was observed in a video) because the polymers also provide resistance by blocking the growing path of SAT. Since the GELSAT-4 is reversible between two states without any leakage, it is suggested that the polymer network inside it is strong enough to survive during crystallization, while the smooth growing edge is also helpful in preventing the network from being corrupted.
- the highest temperature that can be reached after solidification is 49.5 °C for pure SAT, while the GELSAT-4 can still achieve 46.2 °C even with a decrease in the weight ratio of crystals. With a higher weight ratio of polymers, the heat-releasing rate will become even slower.
- the GELSAT can advantageously be customized to meet different requirements of various discharge rates.
- IR images were also taken after the sample was triggered from the center in the sample bottle ( Figure 7(e)).
- GELSAT-4 showed an excellent distribution of heat during the crystallization as the expanding heated area is always in a regular round shape, indicating that the radius of heat spreading is equal in each direction.
- the GELSAT-4 is well synthesized with a homogenous structure, which makes it a reliable heat battery material.
- the curve of H d shows slight fluctuation as the cycle time increases, while the highest value was either at the top or the bottom part alternatively. This further strengthened the fact from the results of IR images that the GELSAT-4 was homogenously synthesized. In general, the DSC tests confirmed the longterm thermal stability of GELSAT through cycles.
- an inflection point can be observed on the curve of only pure SAT but not the GELSAT, which is considered the phase separation point. This is due to the precipitation of anhydrous SA under a certain temperature from the supersaturated SAT solution, which usually comes with a small amount of heat released. Interestingly, the phase separation point was actually shifting to a lower temperature each time as the cycle time increased. The inventors believe that, after each phase separation, a new liquid phase will form at the top of anhydrous SA, which is less saturated at the current temperature. This will result in a lower and lower precipitation temperature at each cycle. During all cycles, GELSAT-4 showed excellent stability with almost no variation on the heating-cooling curves, while GELSAT-6 was experiencing slower heating and cooling after each cycle. Nevertheless, no sign of phase separation could be observed from both curves of GELSAT.
- Figure 11 shows the heat-releasing curve of GELSAT-4 and GELSAT-6 at the 1 st and 7 th cycles.
- GELSAT-4 there is only a slight difference observed on its crystallization behavior before and after 6 cycles.
- the highest temperature that GELSAT-4 could reach under 10°C was 53.41°C, which dropped by only 1% (0.55°C).
- a large difference could be noticed on the shape of the GELSAT-6 solidification curve. Instead of staying tall and sharp, the peak has become wider and lower over cycles.
- the mean thermal conductivity of pure SAT, GELSAT-4 and GELSAT-6 was obtained by testing each sample for 5 times with KD2-Pro Thermal Analyzer. For all samples, the standard deviation was calculated as only 0.001 W/(m*K). As shown in Figure 12, after being modified with 2 wt% of water and 4 wt% of polymers, the thermal conductivity actually dropped from 0.631 W/(m*K) to 614 W/(m*K), while the value increased to 674 W/(m*K) and is even higher than SAT when 3 wt% of water and 6 wt% of polymers were added.
- Stable supercooling is an original property of SAT, enabling it to preserve energy at a large supercooling degree of over 30°C.
- stable supercooling is crucial as well since it aims for long-term thermal energy storage, mostly at room temperature. If the supercooling is not stable enough and the PCM is triggered spontaneously during storage, a heat waste will occur.
- GELSAT-4 and GELSAT-6 were put into 4 sample bottles separately, 2 for each. They were stored at room temperature and in the fridge (5°C) separately for 3 months. Surprisingly, both 4 samples stayed supercooled stably after 3 months of storage, while they can also be discharged.
- Example 7 varying ratio of acrylamide vs. acrylic acid
- the monomers were acrylic acid and acrylamide, wherein the amount of acrylamide used was varied as compared to the amount of acrylic acid used; the wt/wt ratios of acrylamide versus acrylic acid were 80:20; 60:40; 40:60; 20:80; and 10:90;
- the crosslinker was N,N'-methylenebisacrylamide, used in an amount of 3 wt% compared to the sum of the weight of the monomers (viz. the combined weight of acrylamide, acrylic acid and N,N' -methylenebisacrylamide); and
- the weight percentage of added water used in the preparation of the mixture is half as much as the sum of the weight of the monomers (viz. the combined weight of acrylamide, acrylic acid and N,N' -methylenebisacrylamide).
- GELSAT-4 was prepared according to Example 2. As both anode and cathode, pure silver electrodes (99.9% pure; 2 mm diameter) were used. The cathode was pre-treated by polishing the cathode together with sodium acetate trihydrate (SAT) solid particles with sand paper from lower number to higher number (for example, P800-P1500-P3000), and then immersing the cathode in hot water of about 70 °C to remove extra crystals for 30 minutes. Then, the electrodes were placed into the supercooled GELSAT-4 at a distance of 5-10 mm between the cathode and the anode.
- SAT sodium acetate trihydrate
- a polymer-based flexible material GELSAT was developed using an one-pot green synthesis method. Compared with pure SAT, the GELSAT completely eliminated the phase separation, resulting in a transparent gel with no anhydrous SA observed during the melting state, while the interaction mechanism inside the material was analyzed and revealed. The modified material showed high enthalpy and good thermal stability. With GELSAT-4, an average energy density of over 262.2 J/g could be achieved, which still preserved 260.2 J/g after 20 cycles. The heat releasing rate was decreased by one-third with the addition of polymers for GELSAT-4, which could be also adjusted by controlling the ratio of polymers to suit different application backgrounds. TGA tests showed that under 105°C, the GELSAT-4 still preserved 68.14% of weight, 5.03% higher than the value of pure SAT which is 63.11%.
- the mechanical properties of the GELSAT are also unique. Different from traditional materials, the GELSAT is not in a liquid state, but a gel state that prevents leakage. The polymer-modified materials could easily switch from an elastic form to a solid form by charging and discharging, while the stiffness of the gel could be manipulated by changing the ratio of polymers inside it. With its superb energy storage property and flexibility, GELSAT can be utilized in various backgrounds of research or industry, as a highly efficient and sustainable energy solution.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Combustion & Propulsion (AREA)
- Thermal Sciences (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
La présente invention concerne des compositions comprenant un matériau à changement de phase et un réseau polymère, ainsi que des procédés de fabrication ou d'utilisation de celles-ci. Le réseau polymère est un copolymère contenant des résidus monomères avec un groupe amide et des résidus monomères avec un groupe acide carboxylique. Les compositions de l'invention présentent des propriétés avantageuses, y compris mécaniques ( par exemple . Flexibilité, retrait réduit) et thermique (chaleur latente améliorée, excellente stabilité de cycle).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22202501.7 | 2022-10-19 | ||
EP22202501 | 2022-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024085756A1 true WO2024085756A1 (fr) | 2024-04-25 |
Family
ID=83899578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2023/050547 WO2024085756A1 (fr) | 2022-10-19 | 2023-10-19 | Matériaux à changement de phase dans des réseaux polymères |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024085756A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0133803A2 (fr) * | 1983-08-12 | 1985-03-06 | Ciba Specialty Chemicals Water Treatments Limited | Compositions pour le stockage de l'énergie thermique |
US4537695A (en) * | 1982-02-23 | 1985-08-27 | Malcolm Hawe | Thermal energy storage compositions |
EP0273779A1 (fr) * | 1987-01-02 | 1988-07-06 | Sumitomo Chemical Company, Limited | Procédé pour produire des matériaux de stockage de la chaleur |
-
2023
- 2023-10-19 WO PCT/NL2023/050547 patent/WO2024085756A1/fr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537695A (en) * | 1982-02-23 | 1985-08-27 | Malcolm Hawe | Thermal energy storage compositions |
EP0133803A2 (fr) * | 1983-08-12 | 1985-03-06 | Ciba Specialty Chemicals Water Treatments Limited | Compositions pour le stockage de l'énergie thermique |
EP0273779A1 (fr) * | 1987-01-02 | 1988-07-06 | Sumitomo Chemical Company, Limited | Procédé pour produire des matériaux de stockage de la chaleur |
Non-Patent Citations (1)
Title |
---|
POSTMA ET AL., ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 56, 2017, pages 1794 - 1798 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yan et al. | Nanoconfining cation-π interactions as a modular strategy to construct injectable self-healing hydrogel | |
Samanta et al. | Synthesis, characterization, swelling and drug release behavior of semi-interpenetrating network hydrogels of sodium alginate and polyacrylamide | |
Jiao et al. | Rigid and strong thermoresponsive shape memory hydrogels transformed from poly (vinylpyrrolidone-co-acryloxy acetophenone) organogels | |
Soo et al. | Rapid UV-curable form-stable polyethylene-glycol-based phase change material | |
US10767093B2 (en) | Phase change compositions | |
CN103145920B (zh) | 一种温度、pH、紫外光多刺激响应半互穿网络纳米复合水凝胶的制备方法 | |
TW201236781A (en) | Process for producing silver nanowires and agent for controlling growth of silver nanowires | |
US11560503B2 (en) | Stable salt hydrate-based thermal energy storage materials | |
Zhang et al. | A Smart Design Strategy for Super‐Elastic Hydrogel with Long‐Term Moisture, Extreme Temperature Resistance, and Non‐Flammability | |
Wang et al. | Hierarchical networks of anisotropic hydrogels based on cross-linked Poly (vinyl alcohol)/Poly (vinylpyrrolidone) | |
CN102604309B (zh) | 一种双疏聚合物膜及其制备方法 | |
Jain et al. | Thermoresponsive cryogels of poly (2-hydroxyethyl methacrylate-co-N-isopropyl acrylamide)(P (HEMA-co-NIPAM)): fabrication, characterization and water sorption study | |
WO2024085756A1 (fr) | Matériaux à changement de phase dans des réseaux polymères | |
Janovák et al. | Swelling properties of copolymer hydrogels in the presence of montmorillonite and alkylammonium montmorillonite | |
Young et al. | Thermodynamic analysis on the cononsolvency of poly (vinyl alcohol) in water–DMSO mixtures through the ternary interaction parameter | |
Gao et al. | Microgel-enhanced thermal-sensitive hydrogel electrolyte enables active heat management, controllable energy storage and mechanical flexibility of supercapacitors | |
Peng et al. | MXene interlayer space expansion: Alleviating coulomb attraction and steric resistance on multivalent charge carriers toward micro-supercapacitors with enhanced areal energy density | |
Rajagopalan et al. | Strong, thermo-reversible salogels with boronate ester bonds as thermal energy storage materials | |
Yin et al. | High-enthalpy biphasic phase change organogels with shape memory function based on hydrophobic association and H-bonding interaction | |
Wan et al. | Synthesis and swelling properties of a pH‐and temperature‐dual responsive hydrogel by inverse microemulsion polymerization | |
Liu et al. | Double-network shape memory organohydrogel prepared by one-pot polymerization | |
Rajagopalan et al. | Hybrid Polymer Salogels for Reversible Entrapment of Salt-Hydrate-Based Thermal Energy Storage Materials | |
CN115850576B (zh) | 一种柔性高潜热低温相变储能凝胶及其制备方法和应用 | |
Chew | Development of novel bio-degradable electrolyte based on polylactide (PLA) for lithium rechargeable battery | |
Trandafilović et al. | Preparation and optical properties of CdS nanoparticles dispersed in poly (2-(dimethylamino) ethyl methacrylate-co-acrylic acid) co-polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23794118 Country of ref document: EP Kind code of ref document: A1 |